Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Healthy Living Europe.
Press releases published on June 4, 2025
Sionna Therapeutics Announces Positive Phase 1 Data for NBD1 Stabilizers SION-719 and SION-451 and Advances Both Programs in Clinical Development for Cystic Fibrosis
GlobeNewswire
·
June 4, 2025
SION-719 and SION-451 were generally well tolerated and achieved desired pharmacokinetic targets that reinforce their potential as either an add-on to standard of care or in a Sionna dual combination Sionna plans to advance SION-719 to a Phase 2a proof-of- …
Purple Biotech Announces Poster Presentation at EACR 2025 on its Novel CAPTN-3 Tri-Specific Antibody Platform
GlobeNewswire
·
June 4, 2025
REHOVOT, Israel, June 04, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance, …
Helius Medical Technologies, Inc. Compliant with Nasdaq Bid Price Rule Listing Criteria
GlobeNewswire
·
June 4, 2025
NEWTOWN, Pa., June 04, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today …
Corvus Pharmaceuticals Announces Full Data from Cohort 3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis
GlobeNewswire
·
June 4, 2025
Cohort 3 demonstrates earlier and deeper responses compared to cohorts 1-2 All three cohorts show separation from placebo with statistically significant difference from placebo at day 28 Cohort 3 demonstrates clinically meaningful reduction in itch as …
Fractyl Health and Bariendo Sign Letter of Intent to Prepare for Potential Offering of Revita® Across its Bariatric and Metabolic Endoscopy Centers Nationwide
GlobeNewswire
·
June 4, 2025
Collaboration is designed to implement a highly scalable clinical pathway for Revita in post GLP-1 weight maintenance, pending FDA approval, potentially benefiting millions of eligible patients Rising interest from patients and payers for an off-ramp from …
Vigil Neuroscience Provides Update on Iluzanebart Phase 2 IGNITE Trial in ALSP
GlobeNewswire
·
June 4, 2025
WATERTOWN, Mass., June 04, 2025 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced an update on …
Upstream Bio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
GlobeNewswire
·
June 4, 2025
WALTHAM, Mass., June 04, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced that Rand Sutherland, MD, …
Sharps Technology Begins Shipments Across Three Customer Orders Under Previously Announced Purchase Agreements
GlobeNewswire
·
June 4, 2025
Shipments include initial deliveries of SecureGard™ and SoloGard™ smart safety syringes from its Hungary-based manufacturing facility Deliveries mark the Company’s transition to a commercial-stage, revenue-generating company NEW YORK, June 04, 2025 (GLOBE …
Design Therapeutics Announces Start of Friedreich Ataxia Patient Dosing Ex-U.S. in its RESTORE-FA Phase 1/2 Multiple-Ascending Dose Trial of DT-216P2
GlobeNewswire
·
June 4, 2025
Initial Data from the Ongoing, Blinded Phase 1 Single-Ascending Dose Trial Has Demonstrated Favorable Safety and Pharmacokinetics IND Application Submitted to Expand RESTORE-FA Trial to U.S. Sites; Notice Received from FDA Placing Clinical Hold on IND …
Revive Therapeutics Advances with Next-Generation Bucillamine Development
GlobeNewswire
·
June 4, 2025
TORONTO, June 04, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company dedicated to developing innovative therapeutics for critical medical needs, is …
Accumulus Synergy and Veeva Systems Partner to Advance Regulatory Transformation and Connectivity
GlobeNewswire
·
June 4, 2025
BURLINGAME, Calif., June 04, 2025 (GLOBE NEWSWIRE) -- Today, Accumulus Synergy (“Accumulus”) announced a strategic partnership with Veeva Systems (“Veeva”) focused on enabling connectivity to help the life sciences industry more effectively exchange …
Accumulus Synergy und Veeva Systems gehen eine Partnerschaft ein, um die Transformation der Regulierung und die Konnektivität voranzutreiben
GlobeNewswire
·
June 4, 2025
BURLINGAME, Kalifornien, June 04, 2025 (GLOBE NEWSWIRE) -- Accumulus Synergy („Accumulus“) hat heute eine strategische Partnerschaft mit Veeva Systems („Veeva“) bekannt gegeben, deren Schwerpunkt auf der Bereitstellung von Konnektivität liegt, um die Life- …
アキュミュラス・シナジー (Accumulus Synergy) とヴィーバ・システムズ (Veeva Systems)、規制の変革と接続性の促進に向けて提携
GlobeNewswire
·
June 4, 2025
カリフォルニア州バーリンゲーム発, June 04, 2025 (GLOBE NEWSWIRE) -- 本日、アキュミュラス・シナジー (「アキュミュラス」) は、ライフサイエンス業界が世界中の各国規制当局 (NRA) と規制対象情報をより効果的に交換できるよう支援することを目的とした、接続性の実現に焦点を当てたヴィーバ・システムズ (「ヴィーバ」) …
Accumulus Synergy et Veeva Systems s’associent afin d’accélérer la transformation réglementaire et la connectivité
GlobeNewswire
·
June 4, 2025
BURLINGAME, Calif., 04 juin 2025 (GLOBE NEWSWIRE) -- Accumulus Synergy (« Accumulus ») a annoncé aujourd’hui un partenariat stratégique avec Veeva Systems (« Veeva ») axé sur la mise en place de solutions de connectivité permettant au secteur des sciences …
TOLREMO therapeutics Announces TT125-802 is the First CBP/p300 Bromodomain Inhibitor to Show Clinical Activity in Solid Tumors
GlobeNewswire
·
June 4, 2025
- Deep and durable responses in drug-resistant KRAS-G12C- and EGFR-mutant NSCLC - Best-in-class safety profile highlights potential for development in combination to treat patients with KRAS-G12C-mutant NSCLC, EGFR-mutant NSCLC and R/R multiple myeloma …
Sagimet Biosciences Announces Positive Phase 3 Results for Denifanstat for the Treatment of Moderate-to-Severe Acne from Partner Ascletis
GlobeNewswire
·
June 4, 2025
Denifanstat met all primary and secondary endpoints versus placebo Denifanstat was well tolerated Oral FASN inhibitors offer a novel mechanism of action for the potential treatment of moderate to severe acne Sagimet initiated first-in-human Phase 1 …
Molecular Health and Axxam enter into a strategic partnership to bolster the discovery of innovative targets in drug development
GlobeNewswire
·
June 4, 2025
MILAN, Italy and HEIDELBERG, Germany, June 04, 2025 (GLOBE NEWSWIRE) -- Axxam S.p.A., a premier provider of integrated early discovery services, and Molecular Health GmbH, a leader in artificial intelligence (AI)-driven development solutions, are …
Philips to repurchase up to 6 million shares to cover long-term incentive plans
GlobeNewswire
·
June 4, 2025
June 4, 2025 Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA) today announced that it will repurchase up to 6 million shares to cover certain of its obligations arising from its long-term incentive plans. At the current share price, the …
OSE Immunotherapeutics strengthens Growth Strategy: Accelerates key pillars of Inflammation and Immuno-Oncology
GlobeNewswire
·
June 4, 2025
OSE Immunotherapeutics strengthens Growth Strategy: Accelerates key pillars of Inflammation and Immuno-Oncology Ignites strong momentum in immunology …
OSE Immunotherapeutics renforce sa stratégie de croissance : Accélération des programmes clés dans l'inflammation et de l'immuno-oncologie
GlobeNewswire
·
June 4, 2025
OSE Immunotherapeutics renforce sa stratégie de croissance : Accélération des programmes clés dans l'inflammation et de l'immuno-oncologie Insuffler un nouvel élan en immunologie et inflammation grâce au développement de lusvertikimab en s’appuyant sur un …